American Society of Hematology
Key bone marrow protein identified as potential new leukemia treatment target
A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be ...
Cancer
Apr 15, 2013 |
not rated yet |
0
Leading leukemia experts: High leukemia treatment costs may be harming patients
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according ...
Cancer
Apr 25, 2013 |
not rated yet |
0
Study suggests stem cell transplant survivors at increased risk of developing heart disease
New research appearing online today in Blood, the journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing hear ...
Cardiology
Oct 03, 2012 |
not rated yet |
0
|
Cord blood effective alternative to matched donor stem cells for kids with rare disorder
Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's ...
Medical research
Mar 14, 2013 |
5 / 5 (1) |
0
Rituximab promotes long-term response for patients with immune destruction of platelets
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of ...
Pediatrics
May 07, 2012 |
not rated yet |
0
Genotype predicts treatment related mortality (TRM) in African-American and Asian pediatric AML patients
New research suggests that the presence of a specific genetic marker, known as WT1 SNP rs16754, may be associated with reduced toxicity from chemotherapy in African-American and Asian children with acute myeloid leukemia ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Risk of leukemia after cancer chemotherapy persists
While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of ...
Cancer
Feb 14, 2013 |
5 / 5 (1) |
0
ASH international clinical collaboration replicates high cure rate of APL in developing countries
Data published online today in Blood, the Journal of the American Society of Hematology (ASH) describe the work of an ASH international clinical network collaborative focused on modernizing treatment protocols for patien ...
Cancer
Jan 14, 2013 |
not rated yet |
0
Genetic susceptibility to anthracycline-related congestive heart failure (CHF) in survivors of hematopoietic cell transp
Researchers have identified specific genetic factors that are associated with heart failure in patients who have undergone hematopoietic stem cell transplantation (HCT) for blood cancer.
Medical research
Dec 09, 2012 |
not rated yet |
0
ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic
New research demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute ...
Cancer
Dec 09, 2012 |
not rated yet |
0
A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events
In the first randomized clinical trial assessing the proper target hematocrit level, or percentage of red blood cells that should be maintained in patients with polycythemia vera (PV), researchers have concluded that the ...
Medical research
Dec 09, 2012 |
not rated yet |
0
Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivo
Researchers have demonstrated that combination therapy with PU-H71 and ruxolitinib increases the durability and effectiveness of a treatment that had previously shown limited utility for patients with myelofibrosis.
Cancer
Dec 09, 2012 |
not rated yet |
0
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today ...
Cancer
Dec 09, 2012 |
5 / 5 (1) |
0
Survey shows breakthrough medical research relies heavily on NIH funding
A survey highlighting the correlation between today's cutting edge medical research and the National Institutes of Health (NIH) funding was released today at the 54th Annual Meeting of the American Society of Hematology (ASH), ...
Other
Dec 10, 2012 |
not rated yet |
0
